Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing
Status:
Completed
Trial end date:
2019-10-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of a sunitinib administration schedule
2/1 (2 weeks of treatment followed by 1 week without) compared to a schedule 4/2 (4 weeks of
treatment followed by 2 weeks without) on cardiopulmonary function in subjects with renal
cell carcinoma. Subjects will be randomized 1:1 to one of two arms: 4/2 schedule of sunitinib
administration or 2/1 schedule of sunitinib administration. Cardiopulmonary function will be
assessed at baseline, week 4 (4/2 schedule only), week 5 (2/1 schedule only) and week 12. The
investigators hypothesize that schedule 2/1 of sunitinib is not only better tolerated but
will be associated with less fatigue and functional cardiovascular/muscular toxicity than the
4/2 schedule.